Galantamine counteracts development of learning impairment in guinea pigs exposed to the organophosphorus poison soman: clinical significance
- PMID: 21784098
- PMCID: PMC5673497
- DOI: 10.1016/j.neuro.2011.07.001
Galantamine counteracts development of learning impairment in guinea pigs exposed to the organophosphorus poison soman: clinical significance
Abstract
Galantamine, a drug used to treat Alzheimer's disease, protects guinea pigs against the acute toxicity and lethality of organophosphorus (OP) compounds, including soman. Here, we tested the hypothesis that a single exposure of guinea pigs to 1xLD50 soman triggers cognitive impairments that can be counteracted by galantamine. Thus, animals were injected intramuscularly with saline (0.5 ml/kg) or galantamine (8 mg/kg) and 30 min later injected subcutaneously with soman (26.3 μg/kg) or saline. Cognitive performance was analyzed in the Morris water maze (MWM) four days or three months after the soman challenge. Fifty percent of the saline-injected animals that were challenged with soman survived with mild-to-moderate signs of acute toxicity that subsided within a few hours. These animals showed no learning impairment and no memory retention deficit, when training in the MWM started four days post-soman challenge. In contrast, animals presented significant learning impairment when testing started three months post-challenge. Though the magnitude of the impairment correlated with the severity of the acute toxicity, animals that presented no or only mild signs of toxicity were also learning impaired. All guinea pigs that were treated with galantamine survived the soman challenge with no signs of acute toxicity and learned the MWM task as control animals, regardless of when testing began. Galantamine also prevented memory extinction in both saline- and soman-challenged animals. In conclusion, learning impairment develops months after a single exposure to 1xLD50 soman, and galantamine prevents both the acute toxicity and the delayed cognitive deficits triggered by this OP poison.
Copyright © 2011 Elsevier Inc. All rights reserved.
Conflict of interest statement
The authors declare that there are no conflicts of interest.
The use of galantamine as an antidote against OP poisoning is protected under the International Patent Application PCT/US05/33789 filed on September 23, 2005.
The opinions or assertions contained herein are the private views of the authors and are not to be construed as reflecting the view of the National Institutes of Neurological Disorders and Stroke, the Department of the Army, the Department of Defense, or the federal government.
Figures
References
-
- Albuquerque EX, Deshpande SS, Kawabuchi M, Aracava Y, Idriss M, Rickett DL, Boyne AF. Multiple actions of anticholinesterase agents on chemosensitive synapses: molecular basis for prophylaxis and treatment of organophosphate poisoning. Fundam Appl Toxicol. 1985;5:S182–203. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
